NDC codes

FDA NDC Directory
Product NDC (as listed)55513-479Labeler and product segments. Claims need a package NDC.
Product NDC at billing width55513-0479Add the package segment from the table below.
Package NDCs as listed with the FDA, and the 11-digit 5-4-2 form used on claims. The highlighted digit is the added leading zero.
Package NDC11-digit (billing)PackageCopy
55513-479-01555130479011 SYRINGE in 1 CARTON (55513-479-01) / .4 mL in 1 SYRINGEMarketed from Aug 14, 2023
55513-479-02555130479022 SYRINGE in 1 CARTON (55513-479-02) / .4 mL in 1 SYRINGEMarketed from Aug 14, 2023

How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules

Product information

Brand name (proprietary)
Amjevita
Generic name (nonproprietary)
adalimumab-atto
Active ingredients
Adalimumab — 40 mg/.4mL
Dosage form
Injection
Route
Subcutaneous
Labeler
Amgen, Inc
Product type
Prescription drug
Marketing category
BLA — Biologics License ApplicationApplication BLA 761024
Marketing start
Listing expires
Other FDA classes
Monoclonal (Chemical structure)Tumor Necrosis Factor Receptor Blocking Activity (Mechanism)
Identifiers
Product ID 55513-479_3657cc39-5ccd-49af-8f85-b622acc243d9SPL ID 3657cc39-5ccd-49af-8f85-b622acc243d9SPL set ID 9c44bd5b-4464-40a4-8933-8680950f00f2RxCUI 2627711, 2627717, 2627719, 2627722, 2627724, 2627725, 2634478, 2634479, 2663901, 2663904, 2663906, 2663907, 2663908, 2663910, 2663912, 2663913, 2663914, 2663915UNII FYS6T7F842UPC 6377113400015

Billing references

What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.

HCPCS codeMed-Code curated

J0135 — Injection, adalimumab, 20 mg

Billing unit: 20 mg. Units on the claim = dose given ÷ 20 mg.

Adalimumab is usually self-administered and dispensed through a pharmacy benefit. Adalimumab biosimilars are listed under their own names.

Administration

Drug administration (CPT 96360–96549)

When a clinician administers the drug, the administration is reported separately. Codes in this range cover hydration, therapeutic injections and infusions, and chemotherapy or other complex drug administration. The right code depends on route, duration and drug type, and self-administered drugs are not billed this way.

How CPT relates to drug billing

NDC on a medical claim

N455513047901 followed by a unit qualifier and the quantity

Package 55513-0479-01. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier

Product label

Current FDA label (SPL), effective . This label includes a boxed warning.

Indications (excerpt from the label)

AMJEVITA is a tumor necrosis factor (TNF) blocker indicated for: Reducing signs and symptoms, inducing major clinical response, inhibiting the progression of structural damage, and improving physical function in adult patients with moderately to severely active rheumatoid arthritis . ( 1.1 ) Reducing signs and symptoms of moderately to severely active polyarticular juvenile idiopathic arthritis in patients 2 years of age and older. ( 1.2 ) Reducing signs and symptoms, inhibiting the progression of structural damage, and improving physical function in adult patients with active psoriatic arthritis . ( 1.3 ) Reducing signs and symptoms in adult patients with active ankylosing spondylitis . ( 1…

Excerpt only. Read the full label for complete information.

Full label on DailyMed (opens in a new tab)

Other NDCs under BLA 761024

Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.

FDA NDC Directory listings under BLA 761024
ProductStrengthForm · routeLabelerProduct NDC
Amjevitaadalimumab-attoAdalimumab 80 mg/.8mLInjectionSubcutaneousAmgen USA Inc.72511-481
Amjevitaadalimumab-attoAdalimumab 40 mg/.8mLInjectionSubcutaneousAmgen USA Inc.72511-400
Amjevitaadalimumab-attoAdalimumab 40 mg/.4mLInjectionSubcutaneousAmgen USA Inc.72511-479
Amjevitaadalimumab-attoAdalimumab 40 mg/.4mLInjectionSubcutaneousAmgen USA Inc.72511-482
Amjevitaadalimumab-attoAdalimumab 20 mg/.2mLInjectionSubcutaneousNuvaila Limited84612-399
Amjevitaadalimumab-attoAdalimumab 40 mg/.4mLInjectionSubcutaneousNuvaila Limited84612-479
Amjevitaadalimumab-attoAdalimumab 80 mg/.8mLInjectionSubcutaneousNuvaila Limited84612-481
Amjevitaadalimumab-attoAdalimumab 40 mg/.4mLInjectionSubcutaneousNuvaila Limited84612-482
Amjevitaadalimumab-attoAdalimumab 20 mg/.4mLInjectionSubcutaneousAmgen, Inc55513-411
Amjevitaadalimumab-attoAdalimumab 20 mg/.2mLInjectionSubcutaneousAmgen, Inc55513-399
Amjevitaadalimumab-attoAdalimumab 40 mg/.8mLInjectionSubcutaneousAmgen, Inc55513-400
Amjevitaadalimumab-attoAdalimumab 40 mg/.8mLInjectionSubcutaneousAmgen, Inc55513-410
Amjevitaadalimumab-attoAdalimumab 10 mg/.2mLInjectionSubcutaneousAmgen, Inc55513-413
Amjevitaadalimumab-attoAdalimumab 80 mg/.8mLInjectionSubcutaneousAmgen, Inc55513-480
Amjevitaadalimumab-attoAdalimumab 80 mg/.8mLInjectionSubcutaneousAmgen, Inc55513-481
Amjevitaadalimumab-attoAdalimumab 40 mg/.4mLInjectionSubcutaneousAmgen, Inc55513-482
Amjevitaadalimumab-attoAdalimumab 20 mg/.2mLInjectionSubcutaneousAmgen USA Inc.72511-399

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free Med-Code account to keep looking up NDCs, J-codes and drugs.

Create a free accountLog in
Amjevita (adalimumab-atto) NDC 55513-479 · J-Code J0135 | Med-Code